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Dengue viruses (DENV) are members of the Flavivirus family and are thought to 
infect up to 400 million people per annum and have the potential to lead to large 
epidemics with subsequent human and economic consequences. The 2 current 
vaccines being developed are at the clinical trial stage and focus on the induction of 
neutralising antibodies but there are at least 5 different serotypes of the virus and it 
appears that induction of immunity to any one serotype will not subsequently 
provide cross protection to the others. The purpose of this project is to develop an 
immunisation strategy that will provide protection across all serotypes. A common 
antigen expressed by all serotypes is designated NS1 which is a non-structural 
protein expressed on the surface of infected cells. However, on its own NS1 is 
poorly immunogenic so the intention here is to develop a vector system that 
combines the expression of NS1 epitopes with those of a highly immunogenic 
protein derived from Staphylococcus aureus the Staphylococcal immunoglobulin-
binding protein, Sbi. Sbi is composed of a number of separate domains each of 
which has characteristic interactive properties with C3. Previous studies have shown 
that Sbi N-terminal domain IV (Sbi-IV) binds to C3 and its proteolytic fragments, 
however, the Sbi domains III and IV are essential for fluid phase consumption of C3 
activating via the alternative complement pathway.  In this project the domains III 
and IV of Sbi have been cloned and expressed in E. coli and conjugated to NS1. 
These can bind to complement C3, causing cleavage, and lead to the generation of 
C3d which is able to crosslink binding between the NS1 antigen and complement 
receptor 2 (CR2) present on phagocytic cells and B cells to greatly enhance a TH2 
(antibody) mediated response and ultimately, the generation of memory TH2 cells to 
provide expansion of B cells (plasma cells) producing DENV specific neutralising 
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Dengue is a viral disease transmitted and spread largely by the mosquito genus 
Aedes aegypti (and to some extent A. Albopictus) which is easily recognised by the 
silvery white pattern on its scales and has become endemic in many tropical areas of 
Africa and Asia. The virus is largely spread by female mosquitoes when they prey 
on large mammals and humans as they require a blood meal to produce eggs. The 
virus is normally present in the salivary glands of the mosquito, so upon biting the 
host the virus is transmitted and then propagates in the host (1, 2).  
The mosquito – human - mosquito cycle of transmission leads to a typical cycle 
being: infected mosquito bite leading to (after about 4 days) acute viremia in the 
host which usually lasts for about 5 days and then the development of symptoms of 
dengue which can last for a week. The mosquito vectors become infected when they 
feed on humans during the four/five-day period of viraemia. The virus passes from 
the mosquito intestinal tract to the salivary glands after an extrinsic incubation 
period, a process that takes approximately 10 days and is most rapid at high ambient 
temperatures (3). Mosquito bites after the extrinsic incubation period result in 
infection, which might be promoted by mosquito salivary proteins (4). 
Although the many cases of Dengue fever are misclassified or indeed under-reported 
it is generally recognised that there are as many as 400 million Dengue infections 
per annum of which about a quarter are shown as clinically relevant infections. From 
these figures published by the World Health Organisation (WHO) it has been 
estimated that up to half a million people require hospitalisation because of Dengue 
fever per annum (5). Following infection there are no specific drug treatments 
available and patient survival depends largely on maintaining patient homeostasis 
through transfusion of fluids. 
The Dengue virus is a positive sense single stranded RNA virus with 10 encoded 
genes. The genome is translated as a single polypeptide which is subsequently 
cleaved into the 10 encoded proteins. Of these 10, three are capsid (C), envelope (E) 
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and membrane (M) proteins and the other 7 are non-structural proteins that are 
important in viral replication and assembly (Figure 1)(6, 7). 
 
Figure 1: Dengue virus genome diagram shows the capsid (C), envelope (E) and membrane (M) 
proteins and the other 7 are non-structural proteins 
Over a period of time it has become clear that there are a number of different 
serotypes of Dengue virus defined by variations in the structure of vial envelope 
proteins and these have been defined as DEN-1, DEN-2, DEN-3 and DEN-4. The 
serotype classification is largely based on E envelope gene sequence data (1485 bp) 
defining the 4 distinct serotypes but advanced sequencing techniques are likely to 
uncover even greater variations including the recently described 5 serotype (DENV-
5). DENV-2 is associated with most severe disease progression with a greater 
propensity for transmissibility, increased virulence and faster replication (8, 9).  
Recovery from infection by one serotype provides lifelong immunity against that 
particular serotype. However, cross-immunity to the other serotypes after recovery is 
only partial and temporary. Subsequent infections by other serotypes increases the 
risk of developing severe dengue fever (10). 
It has been proposed that the process of infection through dengue virus initial 
exposure and uptake by dendritic cells in the skin proceeds via ICAM3-grabbing 
non-integrin (DC-SIGN) receptors of immature dendritic cells (11) which then 
migrate and mature in regional lymph nodes promoting further presentation of viral 
epitopes and thus enhancement of disease progression through the development of 
inflammation and the recruitment of mature T cells. This phenomenon involves the 
development and maturation of both type 1 and type 2 immune responses and leads 
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to the activation of monocytes and macrophages which can participate in so called 
antibody-dependent enhancement (ADE) (12) (13). ADE is particularly enhanced in 
the presence of phagocytes which naturally take up immune complexes (via Fc 
receptors) formed from DENVs and non-neutralizing antibodies.  There is a 
suggestion that the non-neutralizing antibodies found in recovering patients result 
from either previous heterotypic dengue infections or from low concentrations of 
dengue antibodies of maternal origin found in infant sera (14)(. Thus the co-
existence of four DENV serotypes in a given population might allow the 
augmentation of population based immune protection by the ADE phenomenon 
(15). 
1.1 Current treatment 
The protocols used for dealing with severe dengue infection were developed as long 
ago as the 1960’s following an outbreak affecting many children in Thailand (16) 
and have been gradually refined since then. Accurate diagnosis is vitally important 
in recognising the early signs of disease onset such as a rising haemocrit and falling 
platelet levels as well as abdominal pain and vomiting (although these can also be 
signs of non-dengue related disease) (17). ELISA and real-time PCR tests can also 
aid accurate diagnosis but these are often impractical in real-life settings. In practice, 
treatment is largely through management of fluids but in severe disease this is 
difficult as fluid overload can be just as dangerous as too little fluids (18). 
There have also been considerable efforts applied to the development of anti-dengue 
drugs especially those aimed at the inhibition of viral entry which is mediated by the 
dengue virus E protein and there has been some promising early results (19). Other 
potential targets are the proteins NS3 and NS5 which have a pivotal role in cell 
replication but these are very much still at the developmental rather than clinical 
trial phase (20). 
As current treatment regimes are often quite ineffective, vaccination is one of the 
main approaches being undertaken to try and prevent infection in the human host. 
However, this is complicated because of the large number of different serotypes of 
the virus. It has been shown that immunisation with one of the 4 well recognised 
Chapter one: Introduction 
5 
 
serotypes does not confer protection against the others and to compound the problem 
it has been well described that following immunisation of one serotype, infection 
with one of the other viral serotypes exacerbates disease progression which is 
referred to as immune enhancement of the disease (10). 
Vaccine design most usually involves inducing the production of ‘neutralising 
antibodies’. Neutralising antibodies are an important aspect of preventing repeated 
infection to microorganisms. They are usually produced towards the later stages of 
an infection and are generally specific for the receptor ligands on the microorganism 
preventing binding to targeted host tissues. In the case of DENV infections where up 
to 4 or 5 separate and discrete subtypes have been shown to exist, it has been 
suggested that the partial cross-reactivity of antibodies induced by an earlier 
infection of one DENV subtype may not be of sufficient avidity to neutralise a 
secondary infection with a discrete subtype and rather than give protection against 
infection may provide a degree of opsinisation enhancing uptake of the virus into 
antigen presenting cells (e.g. macrophages) leading to increased spread throughout 
the body and enhanced viral replication – so called antibody-dependent 
enhancement (ADE) (12, 21). 
 
So currently there are no really effective vaccines against Dengue virus but a 
number of approaches with the backing of WHO are being tested. The most 
advanced trials are with attenuated forms of the virus normally given in 
combinations of serotypes. As mentioned above, one of the main concerns about 
inducing immunity to Dengue following immunisation is the problem of disease 
enhancement and it has thought that by immunising simultaneously with multiple 
sub-types of the virus this could be overcome. However, preliminary evidence 
suggests that even this approach may not circumvent the problem of disease 
enhancement caused by the production of neutralising antibodies produced with low 
affinity and sub-optimal titres (22, 23). 
 
As discussed earlier, current vaccine strategies are not effective because of the broad 
range of serotypes existing in wild populations and, indeed, may actually lead to 
greater pathogenesis because of disease enhancement. Thus targeting the non-
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structural and highly conserved protein for vaccine development could provide an 
important new approach to this serious health problem.  
 
1.2 Innate immunity 
The immune system consists of 2 separate ‘arms’ - innate and adaptive immunity. 
While adaptive immunity has the property of being highly specific and also 
possesses ‘memory’ of previous infections it takes a long period to become 
effective. Thus a sudden highly virulent infection can lead to death before adaptive 
immunity is able to neutralise the pathogen by recruitment of T-lymphocytes, B-
lymphocytes and humoral components that include immunoglobulins and cytokines 
(24, 25). This is why the innate immune response plays a vital role as the ‘first line’ 
of immune defence (Figure 2). 
 
The innate immune system on the other hand is able to respond to pathogens and 
recognise pathogenic organisms using pathogen recognition receptors (PRRs) which 
are able to bind to microbial associated molecules or molecular ‘patterns’ present 
only on micro-organisms (pathogen-associated molecular patterns (PAMPs), not 
present in human tissues (26). Examples of PAMPs include Lipoteichoic acid (LTA) 
of Gram-positive bacteria, Lipopolysaccaride (LPS) of Gram-negative bacteria, 
mannan in yeasts, microbial glycolipids and RNA and DNA from viruses. The 
critical element of the innate immune response is its ability to very quickly mount an 
effective defence against viruses and bacteria. The importance of innate immunity to 
protection from microbial infection is illustrated by the fact that there are only very 
rare cases of people found with poorly effective innate immune responses (27-29). 
 




Figure 2: Schematic representation of the roles of innate and adaptive immunity in responding 
to infectious disease (30) 




1.3 The complement system 
The complement system is a crucial arm of the innate immune defence. It consists of 
more than 30 proteins in serum, tissue fluids and on cell surfaces (31). Hepatocytes 
are considered to be the primary site for biosynthesis of complement proteins 
although extra-hepatic sources of complement protein synthesis have also been 
reported which include monocytes, macrophages, pulmonary epithelial cells, 
osteoblasts, adipose tissue and myoblasts (32). There are three different pathways of 
complement activation: namely the classical pathway (CP), the alternative pathway 
(AP) and the lectin pathway (LP) (igure 3). Complement proteases exist in serum as 
inactive zymogens that, upon activation, develop into a cascade of enzymatic 
reactions involving the assembly of proteolytic complexes and the conversion of 
complement-zymogens from their inactive state to an enzymatically active state 
(30). Upon activation, all of the three pathways converge at the C3 cleavage stage 
which is the most crucial step in complement activation. 
 
The classical pathway is mainly initiated by the binding of C1 to antigen-antibody 
complexes (33). Clusters of IgG1, IgG2, IgG3 and IgM molecules on antigen 
surfaces lead to binding of the classical pathway recognition molecule C1q. This 
binding then leads to activation of the associated serine protease C1r. Upon 
activation, C1r cleaves and activates C1s which in turn cleaves C4 into C4a and 
C4b. In a second cleavage step, active C1s cleaves C4-bound C2 into C2a and C2b. 
C4b and C2a stay bound to the surface to form the classical pathway C3 convertase, 
C4bC2a while the C4a and C2b are released into the fluid phase (34-36). In addition 
to the antigen-antibody route of classical pathway activation, some microorganisms 
and compounds have been found to directly initiate the activation of the classical 
pathway including C-reactive protein, Gram-negative bacteria and viral envelopes 
(37).  
 
Another route of complement activation is the lectin pathway. This pathway is 
initiated by the binding of lectin carbohydrate recognition molecules to pathogen 
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surfaces. In the human, more than five different recognition molecules have been 
identified so far, including Mannose Binding Lectin (MBL), ficolins (L-ficolin [also 
known as ficolin-1], M-ficolin [also known as ficolin-2], H-ficolin [also known as 
ficolin-1]) and Collectin-11 (CL-11). The pathway involves three serine proteases 
i.e. MASP-1, MASP-2 and MASP-3 for Mannose binding lectin Associated Serine 
Protease (38-40). 
 
The binding of carbohydrate recognition molecules to their target leads to the 
activation of its associated serine protease. Similarly to the classical pathway 
molecule C1r, MASP-2 cleaves both C4 and C2 generating C4bC2a which is in 
effect the lectin pathway equivalent of C3 convertase. MASP-1, however, has the 
ability to cleave C2 but not C4 (41). The most recently discovered MASP, MASP-3, 
is devoid of enzymatic activity against C2, C3 and C4 (40). However, recent 
publications have claimed that MASP-1 and MASP-3 have the ability to cleave and 
activate the alternative pathway effector enzyme factor D (42). 
 
C3 convertase produced by either the classical pathway or the lectin pathway, 
C4bC2a, cleaves its unique substrate, C3, into two unequally sized fragments, C3a 
(9 kDa) and C3b (171 kDa). C3b binds to C3 convertase to form C5 convertase, 
C4bC2a(C3b)n (35, 43).  
 
The alternative complement pathway (AP) plays a crucial role in immune protection 
and it has been suggested that approximately 80-90% of all complement activation 
goes via the alternative pathway (44). As shown earlier, the key component of the 
initiation of complement activation is by the cleavage of C3 to C3b and other 
cleavage products and this can be initiated through the classical or lectin pathways 
which in turn can activate the highly effective alternative pathway. In the alternative 
pathway of complement activation, factor B (FB) binds to a C3b-bound activator 
surface and undergoes conformational changes exposing a new cleavage site for 
factor D (FD). FD cleaves C3bB to form the alternative pathway C3 convertase 
(C3bBb) and the latter cleaves C3 into C3a and C3b (35, 43) 
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However, there is another route by which C3 can be cleaved using spontaneous 
hydrolysis of native C3 to produce C3(H2O). The thio-ester bond of native C3 
undergoes hydrolysis and that lead to emerge new binding site of FB which allows 
binding of FB to form the C3(H2O)B complex. In turn factor D cleaves factor B in 
that complex to form C3(H2O)Bb which is a further route to the generation of AP 
activation (34, 35). 
 
Following C3 activation, a C5 convertase will be formed by the binding one or more 
molecules of C3b to C3 convertase, C4BC2a(C3b)n or C3bBb(C3b)n, that will 
activate complement C5 via cleaving it into C5a and C5b. The activated C5 
stimulates the assembly of the terminal complement components C6, C7, C8 and C9 
with the formation of the so-called Membrane Attack Complex (MAC). MAC has 
the capacity to insert into target cell membranes with subsequent lead to lysis of 
these susceptible target cells (45).  
 
 
Figure 3: Schematic representation of the complement pathways 
The 3 different complement pathways that have different initiating pathways which converge at the 
C3 cleavage stage which is the most crucial step in complement activation (46). 
 
As a part of the innate immune system, complement protects the body against 
invading pathogens via one or more of the following mechanisms; recruitment of 
immune cells, opsonisation and lysis of pathogens via MAC formation (47).  
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Complement activation leads to a constant release of pro-inflammatory signals, 
including the anaphylatoxins C3a and C5a, which trigger phagocytosis. C3a and C5a 
are strong chemoattractants that trigger activation of phagocytes (i.e. monocytes, 
macrophages and neutrophils) to the site of infection to remove the opsonised cells 
(48). 
 
In spite of the important and crucial role of the complement system in innate 
immune defence against infection, complement activation can have a detrimental 
effect on self-cells and is thus tightly controlled by a number of feedback signals. 
The contribution of the complement system to the pathophysiology and development 
of several autoimmune diseases has been well documented and uncontrolled 
complement activation can also lead to the development of inflammatory diseases 
such as Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Haemolytic Uremic 
Syndrome (aHUS), Age-related Macular Degeneration (AMD), and 
membranoproliferative glomerulonephritis (49). 
 
Viral infections have the ability to initiate the activation all 3 complement pathways. 
For instance, C1q, C3b and C4b can bind directly to viron surfaces leading to 
opsinisation and the recruitment of phagocytic cells and may also directly prevent 
the interaction of viruses with their appropriate receptors preventing uptake (50). In 
addition, C3 has been shown to directly inactivate human immunodeficiency virus 
and the formation of multivalent complexes of viruses, antibodies and complement 
serve to neutralise viral infectivity. The terminal components of the classical 
complement pathway (C5a-C9) have also been shown to directly attack viral 
envelopes leading to pore formation and osmotic lysis and loss of viral viability as 
has been shown for alphaviruses, coronaviruses, herpesviruses, and retroviruses (51, 
52). 
During dengue hemorrhagic fever DHF, the complement cascade is also activated 
and the levels of the complement activation products C3a and C5a correlate with the 
severity of illness (53). Both soluble and membrane-associated NS1 have been 
demonstrated to directly activate human complement and the levels of the terminal 
complement complex (SC5b–9) and plasma NS1 concentration both correlate with 
disease severity, suggesting a link between the virus, complement activation and the 
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development of DHF and dengue shock syndrome (DSS) (54). Alternative 
hypotheses of dengue pathogenesis include the suggestion that secondary T-cell 
responses are blunted because stimulation of the T-cell memory response results in 
the production of heterotypic CD4+ and CD8+ cells that have a diminished capacity 
to neutralise the infection but, at the same time, release inflammatory cytokines that 
contribute to disease severity (55); this leads to the development/maturation of 
DENVs with an increased virulence causing more severe disease (56); and, finally, 
there has been a suggestion that cross-reactivity between the NS1 protein and 
components of human platelets and endothelial cells leads to the production of cross 
reactive antibodies that damage these cells increasing the pathological consequences 
(57). 




1.4 Complement C3d and Staphylococcal Sbi protein as an adjuvant 
strategy 
In the cleavage process which produces C3b from C3, another important fragment is 
produced (C3d), which is the final degradation product of C3. As a natural and 
powerful opsonin, C3d provides an excellent way of switching on Th2 activation. 
C3d binds to complement receptor 2 (CR2) that is located on the surface of follicular 
dendritic cells (FDC), B cells and some subsets of T cells. C3d stimulates antigen 
presentation by FDCs and helps to maintain B cell memory which in turn can be 
highly effective in initiating and perpetuating an immune response, thus acting as an 
adjuvant for any linked antigen (58, 59).  
Vaccine development can be focused through different effector pathways of the 
immune response to establish immunological memory and classical approaches to 
vaccine design try to induce the production of neutralising antibodies which are 
effective against viral infections as these prevent entry of the virus (upon later 
exposure) to its target cells. For this to be successful, it is necessary for the vaccine 
to initiate a Th2 response which induces antibody mediated immunity. The 
Staphylococcus aureus immune evasion protein Sbi is unique in its ability to interact 
with components of both the adaptive and innate arms of the immune system. Sbi 
has 4 domains – Sbi-I and Sbi-II bind IgG and Sbi-IV, on its own, specifically 
inhibits the alternative pathway of complement activation but when linked to Sbi-III 
induces a futile consumption of complement (Figure 4).  
 
Figure 4: Schematic representation of the domain structure of Sbi taken from (60) 
 
Chapter one: Introduction 
14 
 
Thus expression of a combination of Sbi domains III and IV has the potential to 
recruit and activate complement through binding to the C3d component of 
complement (60). Normally activation of B cells and the initiation of B cell clonal 
proliferation requires cross-linking of the target antigen epitope with the appropriate 
B cell surface receptors (BCR) but by combining the antigen with C3d, the 
combined antigen can directly crosslink the BCR on any one B cell precursor with 
CR2, greatly enhancing the potential activation of B cells even when these may have 
a very low precursor frequency. In addition, enhanced expression of C3d can act as a 
chemical attractant, again improving the activation of Th2 directed immunity (59) 
(Figure 5).  
 
Figure 5: diagrammatic representation of how C3d binding to a target antigen via CR2 
This binding can greatly enhance stimulation of B cells and consequently enhance phagocytosis 
leading to enhanced antibody maturation and long-term memory (61) 
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1.5 Dengue non-structural protein 1 (NS1) as a vaccine antigen 
Given the proven difficulties in developing an effective vaccine against the different 
serotypes of the Dengue virus, this project sets out a coherent approach which can 
lead to the induction of neutralising antibodies caused by local complement 
activation and opsonisation of the antigen by using the complement C3d fragment as 
a natural adjuvant. Rather than trying to target the numerous antigens present on the 
various serotypes the project sets out to target the non-structural protein 1 (NS1) of 
the virus that is highly conserved and is present in all serotypes of DENV (62) thus 
overcoming the problem of trying to induce a protective response to the numerous 
subtypes. NS1 is a glycosylated 48kD protein that has been shown to be important 
not only in viral replication but also seems to play a role in immune evasion (63, 
64). 
 
It has also been shown that NS1 is a major target of humoral immunity in patients 
recovering from disease and is also believed to be involved in DENV pathogenesis. 
Some authors have suggested the NS1 protein itself (as well as virons) when taken 
up by endothelial cells in the liver may actually promote and enhance viral infection 
of the liver cells so this evidence supports the concept that the non-structural viral 
protein NS1 plays an important role in DENV disease pathogenesis (53, 65). NS1 is 
also a useful diagnostic marker for the presence of dengue virus using enzyme-
linked immunosorbent assays (ELISAs) as it is secreted and circulates in the plasma 
even at an early stage of viral infection. It has been shown that NS1 can directly 
bind host components of complement which leads to inhibition of complement 
activation in solution (66). The immune response to dengue virus (DENV) infection 
generates high levels of antibodies (Abs) to NS1, particularly in cases of secondary 
infection (67, 68). It has also been suggested that NS1 may contain epitopes that 
mimic self-epitopes present on host molecules intensifying the pathogenic effects of 
DENV infection as seen with DHF and DSS. Increasing evidence for the important 
role of NS1 in the development of DENV pathogenesis thus enhances the case for 
focusing attention on NS1 as a target for inducing protective immunity (54, 69, 70).  
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1.6 Outline of the project objectives 
The project therefore set out to express a pGEX-htb construct (combining the Sbi-
III-IV and NS1 genes) using the pET28a expression system in BL21 E. coli. 
Possibly because of a lack of glycosylation in the E. coli expression system the 
fusion protein was expressed in inclusion bodies because of poor solubility, so a 
large part of the project was devoted to investigating the best method to yield a 
soluble/functional protein which could be characterised by circular dichroism and 
assessed for its functional activity by complement activation assays in vitro. 
 
The key aims of the project were therefore to: 
• Express the vector in E. coli and purify the expressed protein. 
• Characterise the fusion protein biochemically (e.g. sequencing, circular 
dichroism). 
•  Assess the function of the fusion protein in complement activation assays 
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2 Materials and Methods 
2.1 Epression and purification of recombinant Sbi-III-IV-NS1 
2.1.1 Cloning 
The coding sequence of Sbi domains 3 and 4 was cloned into the pET28a 
(Kanr)vector using the NheI and BamHI restriction sites and, in addition, the coding 
sequence of Dengue virus NS1 was inserted using the BamHI and XhoI restriction 
sites to make a plasmid construct that can be expressed in E. coli. The recombinant 
Sbi-III-IV-NS1 carries a N-terminal His-tag for protein purification. (This work was 
performed by Dr Gyles Cozier). See appendix 1 for the coding sequence. 
 
2.1.2 Expression of Sbi-III-IV-NS1 using E. coli BL21 (DE3) 
The E. coli BL21 (DE3) strain was used to express the Sbi-III-IV-NS1 fusion 
protein. Bacteria containing the plasmid were grown overnight in LB medium 
containing a final concentration of 1 mM of Kanamycin at 37°C. 15ml of the 
overnight culture (primary culture) were added to 1L of LB medium containing 1 
mM. Cells were grown at 37°C with shaking at 180 rpm. The expression of the Sbi-
III-IV-NS1 fusion protein was induced at different temperatures i.e. 12°C, 16°C and 
25°C during the exponential growth phase (OD600=0.8) in the presence of 0.5mM 
isopropyl thiogalactoside (IPTG). E. coli cells were then centrifuged at 8000g for 20 
min at different time points including 16h, 12h and 8h after induction. The cell pellet 
was resuspended in 20ml of HisA buffer (20mM Tris + 300mM NaCl + 20mM 
imidazole). The re-suspended cells were sonicated on ice 6 times at 80% amplitude 
for 30 seconds separated by 5 minute intervals and the resulting cell lysate was 
centrifuged at 60,000g for 30min at 4°C.  
 
 




The supernatant was collected and the recombinant protein purified by ion exchange 
chromatography using HiTrapTM HP column (GE Healthcare). The HiTrapTM HP 
chromatography column was operated by using the AKTA purifier system of GE 
Healthcare which allows monitoring the progress of purification and measuring the 
conductivity and UV/Vis absorbance at 280 nm for detecting the proteins. The 
supernatant was loaded onto a 1ml Hitrap column (GE healthcare) using an AKTA 
purifier (GE) with a flow rate of between 0.8ml/min and 1.5 ml/min. The loaded 
column was washed with 5 column volumes of HisA buffer and the bound Sbi-III-
IV-NS1 fusion protein was eluted with HisB (20mM Tris, 300mM NaCl, 500mM 
imidazole) elution buffer.  
2.2 Isolation of the Sbi-III-IV-NS1 plasmid DNA 
 
The E. coli BL21 (DE3) strain did not express the protein as a soluble protein. In 
order to transform the Sbi-III-IV-NS1 plasmid into a different bacterial host as 
another approach to express the required protein, the The pET28a (Kanr) vector and 
Sbi-III-IV-NS1 plasmid DNA was isolated and purified using the GeneJET Plasmid 
Miniprep Kit (Thermo- fisher). Following the manufactures instructions, briefly, 7 
ml of the overnight culture was centrifuged for 10 minutes at 2000 g at 4 OC. The 
supernatant was discarded and the pellet re-suspended with 250 µl of cell re-
suspension solution, mixed by vortex and transferred into a micro centrifuge tube 
followed by adding 250 µl of cell lysis solution and the tubes were then kept for 2-3 
minutes at room temperature (RT). At the end of the incubation, 10 µl of alkaline 
protease solution was added and mixed and then the micro centrifuge tube was left 
at RT for 3 minutes. In the next step, 350 µl of neutralisation solution was added and 
mixed immediately. Samples were spun down at 13,000 g for 10 minutes. The clear 
supernatant was transferred onto a spin column which has a filter (provided by the 
kit) and centrifuged for 60 second. The flow through was discard and the column 
was washed by adding 750 µl of washing buffer to the spin column and the column 
was centrifuged at 13,000 g for 60 seconds.  The flow through was discarded and the 
column left in a safety cabinet for 15 minutes to remove the ethanol and the plasmid 
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DNA was eluted in clean tubes by adding 55-65 µl of Nuclease free water and 
centrifuged at a maximum speed of 13,000 g for 60 seconds and the eluted DNA 
was stored at -20oC. 
2.3 Expression of Sbi-III-IV using Rosetta ™ 2(DE3) 
 
The pET28a (Kanr) vector and of the Sbi-III-IV-NS1 plasmid were extracted from 
the transformed cells using the GeneJET Plasmid kit. The Rosetta™ 2(DE3) 
competent cells were recovered from -20°C and thawed on ice. 5μl of the extracted 
plasmid were added to 10µl of the competent cells and mixed gently, then incubated 
on ice for 20 minutes. After that, cells were heat shocked in a water bath at 42°C for 
45 seconds, to allow uptake of the plasmid by bacterial cells, then transferred 
immediately into ice for another 2 minutes then 900 µl of LB broth was added to the 
tubes and incubated at 37°C for 1-2 hours with gentle shaking at 180 rpm. Two 
different volumes; 50 µl and 100 µl were placed onto LB media plates containing 1 
mM of kanamycin and chloramphenicol antibiotics (35µg/ml) and then incubated 
overnight at 37°C.  The next day, one colony was picked up using a sterile tip then 
inoculated in a universal tube containing 10ml LB medium, and incubated at 37°C 
for overnight with shaking at 180 rpm. For protein expression, the growth culture 
was transferred to a flask containing 1 L of LB medium containing 1 mM of 
kanamycin and 35 μg/ml chloramphenicol and the flask was incubated at 37°C with 
shaking until the OD600=0.8. At this time, protein expression was induced by 
addition of IPTG to a final concentration of 1mM. Bacteria were harvested after 4, 
8, 12 and 18 hours of incubation by centrifugation at 4000 x g, 4ºC, for 20 minutes 
and the cell pellets were re-suspended in PBS for washing. The cells were then 
sonicated on ice for 6 times at 55% amplitude for 30 seconds separated by 5 minutes 
and the cell lysate was centrifuged at 6000 x g for 30 minutes at 4ºC. 
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2.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
In order to identify the molecular weight of the proteins, samples were resolved by 
SDS-PAGE (NOVEX).40 µl of the purified protein was mixed with 10 µl of 6X 
SDS loading dye containing 1% β-mercaptoethanol (reducing conditions) and the 
mixture was heated at 90°C for few minutes. 25 µl of this mixture were loaded into 
12% SDS gel wells. The gels were run at 150 volts for 40 minutes. The gels were 
then stained with Coomassie Brilliant Blue. 
 
In order to identify the molecular weight and visualize the protein bands, gels were 
incubated with Coomassie brilliant blue R-250 (Serva)solution with gentle shaking 
for 20 - 25 minutes and the gel was de-stained by using de-staining solution (30% 
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2.5 Optimization of the expression and purification of inclusion 
bodies 
2.5.1 Optimization of the expression of recombinant Sbi-III-IV-NS1 
To optimize the Sbi-III-IV-NS1 protein expression E. coli BL21 (DE3) strain was 
used. Bacteria containing the plasmid were grown overnight at 37°C with shaking at 
180 rpm in LB medium supplemented with 1 mM of kanamycin. 15ml of the 
primary culture was added to 1L of LB medium containing 1 mM kanamycin. The 
culture was incubated at 37°C until the OD600 reached 0.8. The Sbi-III-IV-NS1 
expression was induced by adding IPTG to a final concentration of 1mM. After 4-5 
hours of incubation, the bacteria were spun down at 8000 g for 20 minutes. The cell 
pellet was washed once in 40 ml of PBS and the pellet was then kept at -80 ºC.  
 
2.5.2 Washing and Processing Protocol for Inclusion Bodies 
 
Following protein expression, four buffers were used to process the cell pellet 
including: lysis buffer, wash buffer 1 (Triton X-100), wash buffer 2 (Urea) and Bug 
Buster. Firstly, the pellet was recovered from -80 ºC and defrosted on ice. Forty 
millilitres of lysis buffer (25mM Tris-HCL pH 8.0, 150 mM NaCl, 0.5 mg/ml 
lysozyme, 1 mM EDTA) were used to dissolve the pellet and a tablet of protease 
cocktail inhibitor (Roche) was added. The mixture was incubated for 30 minutes at 
room temperature (RT) with shaking. A mixer buffer (5 mM MgCl2, 5 μg/ml 
DNAse) was added to the solution and incubated for 15 minutes at RT with shaking 
followed by sonication (amplitude at 60% 8 to 9 pulses, 30 seconds per pulse with 3 
minute between) and then centrifugation at 20,000g for 20 minutes at 4ºC. The 
lysate was collected and supernatant was discarded. The pellet was then re-
suspended in 40 ml of wash buffer 1 (25 mM Tris-HCL pH 8.0, 0.5 M NaCL, 0.5% 
Triton X-100, 1mM EDTA. pH 8). Two sonication pulses were applied before 
further purification followed by centrifugation as in the previous step. After 
discarding the supernatant, wash buffer 2 was used (25mM Tris-HCL pH 8.0, 0.5 M 
NaCl, 1 mg/ml sodium deoxycholate, 1 M Urea) followed by another round of 
sonication and the mixture was then centrifuged. The pellet was washed with 40 ml 
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of 1:10 protein extraction master mix reagent (BugBuster) followed by sonication 
and spun down. After this step the pellet was dissolved in 10 ml of 25 mM Tris-
HCL pH 8.0 buffer. Finally, the suspended protein was distributed into 1ml 
Eppendorf tubes, centrifuged at 13,000 rpm for 10 minutes and the pellets were 
stored at -80 ºC.  
 
2.5.3 Inclusion Bodies – Optimizing solubilisation and refolding 
 
After completing washing and purification of the inclusion bodies, samples were 
dissolved in 50 ml of solubilisation buffer (25 mM Tris-HCL pH 7.5, 8 M Urea with 
5 mM DDT at pH 8) and incubated in a water bath at 42ºC for 15 minutes. 
Subsequently, the suspension was centrifuged to remove any remaining insoluble 
cell debris. The supernatant was collected and the concentration was adjusted to 1 
mg/ml in each experiment to be used for the refolding process as the manufacture 
instructions. 
 
The refolding process was started by screening the optimal refolding buffer using 
the QuickFold™ Protein Refolding Kit (Athena) for the Sbi-III-IV-NS1 protein. The 
kit contains 15 buffers which were screened for their ability to refold the protein. 4 
buffers were then chosen to be used for refolding experiments (see Appendix 3 for 
buffers).  
 
Once the appropriate refolding buffers were determined, 50 ml of the solution 
containing soluble protein was mixed slowly by drop method with the refolding 
buffer at 4ºC overnight, using a 50 ml syringe with gentle stirring. The refolded 
protein was then dialysed against dialysis buffer (25 mM Tris-HCL pH 7.4, 150 mM 
NaCl) at 4ᵒC overnight. 
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2.5.4 Purification using immobilized metal affinity chromatography  
 
To facilitate the purification process, the code for six consecutive histidine residues 
was added to the N-terminus of the Sbi-III-IV-NS1 plasmid insert. The HisGravi 
Trap column (GE Healthcare) provides a rapid purification of Histidine-tagged 
proteins. To obtain the maximum purity of the recombinant protein, a solution 
containing the refolded protein was run through a HisGravi Trap column (GE 
Healthcare) allowing the solution to flow through the column by gravity. The 
column was then washed with 20 ml washing buffer (PBS buffer pH 7.4, containing 
20 mM imidazole). Finally, the protein was eluted using 5 ml elution buffer (PBS 
buffer pH 7.4, containing in order 100mM, 200mM, 300mM and 500mM imidazole) 
to define the optimal elution concentration of imidazole. 
 
2.6 Measurement of the protein concentration 
To measure the Sbi-III-IV-NS1 protein concentration, the Nano drop 2000c 
spectrophotometer (Thermo Scientific) was used, using an extinction coefficient of 
16.29M-1 cm-1. 
 
2.7 Complement activation assay assessment using the Wielisa kit 
The complement system functional activity of the recombinant Sbi-III-IV-NS1 
protein was assessed using Wieslab complement system screening kit (Euro 
Diagnostica, COMPL 300 RUO) in accordance with the enclosed manufacturer 
instruction. The assay system itself uses the principles of ELISA to quantitate the 
functional different pathways of complement activation in human serum by using 
labelled specific monoclonal antibodies that can detect the presence of neo-epitopes 
generated by complement activation. Microtitre plate wells are coated with specific 
lectin, classical or alternative pathway activator i.e. the LPS coated wells for the 
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alternative activation pathway, IgM coated wells for the classical activation pathway 
and mannan coated wells for the MBL activation pathway of complement. 
 
In order to insure that only one pathway is activated in each assay, the diluents used 
in this assay contain pathway-specific blocker. For example, the alternative pathway 
diluent contains Ethylene-bis (oxyethylenenitrilo) tetraacetic acid (EGTA) that 
chelates the calcium required for the classical and the lectin pathway activation. The 
low serum concentration cannot activate the alternative pathway as it requires high 
serum concentration leaving the classical and the MBL pathways intact and in order 
to discriminate between them, the classical pathway is only activated on IgM coated 
strips in presence of divalent ions, calcium and magnesium. The MBL pathway is 
activated on mannan coated wells as the lectin pathway Mannan-Binding Lectin 
(MBL) recognition molecule binds to mannan and activated the complement system 
via the lectin pathway. 
 
In order to investigate the possible roles of the recombinant Sbi-III-IV-NS1 protein 
in complement activation pathways, the recombinant protein was mixed with normal 
human serum to a final concentration of 0.5 mg/ml and incubated for 30 minutes at 
30˚C. The mixture was then diluted 1:101 with the classical pathway and MBL 
pathway diluents (low serum concentration in a buffer containing calcium and 
magnesium), as provided with the kit, and 1:18 with the alternative pathway diluent 
(high serum concentration in a buffer containing magnesium and EGTA). After that, 
100 μL of the diluted serum were added to the corresponding plate wells and 100 μL 
of the positive control (complement reference serum) and negative control sera 
provided were added to other wells. Wells received buffer only were considered as 
blank and plate incubated for one hour at 37°C. Plate was washed three times with 
300 μL of washing solution followed by adding 100 μL of specific alkaline-
phosphatase labelled antibody to a new antigen expressed in C5b-9 complex were 
added to each well and the plate was then incubated at room temperature for 30 
minutes. After washing the plate 3 times, 100 μL of substrate solution was added to 
each well followed by incubation for 30 minutes at room temperature. The 
absorbance, correlated to complement activity, was measured at 405 nm using a 
microplate reader. The blank (diluent) absorbance was subtracted from samples, 
negative and positive control absorbance. The mean of pathway activated was 
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calculated from the formula [sample - negative control]/ [positive control - negative 
control] x100. 
2.8 Circular dichroism (CD) 
Circular dichroism (CD) is a useful method for determining the secondary folded 
structure of proteins and works by determining the asymmetry of molecules due to 
differences in absorption between left- and right- handed circular polarised light 
(71). In essence the CD signal between 190-250 nm and 250-350 nm can indicate 
characteristics such as a-helices and disulphide bonds allowing prediction of 
characteristics such as the presence of helices, b-sheet formation and coiling of the 
protein. Here CD experiments were performed on an Applied Photophysics 
Chiracsan instrument. The experiment was done in three scans at 20°C across a 
wavelength range of 200-300 nm and the path length was set at 1 mm and scanning 
intervals were 0.5 seconds. The protein sample concentration was 0.5 mg/ml in PBS.  
 
2.9 Western blotting 
Following expression of the pET28a plasmid containing the insert for the Sbi-III-IV-
NS1 fusion protein in E. coli BL21, the bacteria were lysed and following SDS-
PAGE and western blotting were performed to identify the Sbi-III-IV-NS1 
recombinant protein. The SDS-PAGE separated proteins were transferred 
electrophoretically onto a nitrocellulose membrane at 25V for 12 minutes in transfer 
buffer. The membrane was then blocked with blocking buffer (5% skimmed milk 
in TBS) at room temperature, followed by washing the membrane twice with 
TBS/Tween-20 and the membrane was then incubated for 1h at RT with polyclonal 
rabbit anti-Sbi antibody [kind gift from Prof Timothy Foster, Trinity College 
Dublin] diluted 1:5000 in wash buffer. After that, the membrane was washed 3 times 
for 10 minutes each and incubated with HRP conjugated goat anti-rabbit IgG 
antibody (Thermo-Fisher, 815-968-0747) diluted 1:5000 in wash buffer for 1h. After 
this, the membrane was extensively washed (3 times for 10 minutes each). The 
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antibody was probed by using Pierce ECL western blotting substrate (Thermo 
Scientific). The last step was to expose the membrane to a light sensitive film before 
being developed and photographed. 
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3.1 Expression and purification of recombinant Sbi-III-IV-NS1 
The purpose of the project was to define and optimise a method for obtaining 
efficient expression of the hybrid protein Sbi-III-IV-NS1. The Sbi-III-IV-NS1 
construct was expressed using the pET28a vector in E. coli BL21. This vector is 
commonly used as it incorporates a sequence that includes a repetitive histidine 
sequence (HisTag) to be incorporated at the N terminal of the transcribed 
recombinant protein and thus allows purification using nickel column affinity 
chromatography. 
 
Sbi-III-IV-NS1 expression in E. Coli BL21 (DE3) was found to be present in 
inclusion bodies in all the conditions that were tried including different temperatures 
and different IPTG concentrations. It is quite common for the expression of 
recombinant proteins in E. coli to be found in inclusion bodies due to aggregation of 
the protein largely because prokaryotic cells do not glycosylate expressed proteins 
and these then become aggregated and form inclusion bodies where the protein is 
likely to be misfolded and inactive. Figure (6 A-B) shows SDS gel separation of the 
transformed bacterial proteins indicating that most of the proteins present 
accumulated as inclusion bodies.  
 
The Sbi-III-IV-NS1 recombinant protein was purified by affinity chromatography 
using a HisTrapTM HP column (GE Healthcare) which was operated using the 
AKTA purifier system. The sample was loaded onto a 1ml Hitrap column using the 
AKTA purifier (GE) and the loaded column was washed with 5 column volumes of 
HisA buffer and the bound Sbi-III-IV-NS1 fusion protein was eluted with HisB 
(20mM Tris, 300mM NaCl, 500mM imidazole) elution buffer. Figures 7 and 9 show 
the purification of Sbi-III-IV-NS1 using the AKTA purifier then judged by SDS gel 
(Figure 8). 
 





Figure 6: Expression trials for Sbi-III-IV-NS1 
This figure shows a 12% SDS-gel stained with Coomassie blue of samples from E. coli expressing 
the Sbi-III-IV-NS1 fusion protein. The tracks include samples taken from the supernatant of un-
induced cultures, supernatant from cultures induced with IPTG, bacterial extracts (after sonication) of 
the soluble fraction and extracts from the insoluble (bacterial pellet) fraction. The molecular weight 
ladder is shown in the left hand column. The transformed bacteria were cultured at both 25oC (A) and 




Figure 7: Purification of Sbi-III-IV-NS1 on AKTA affinity chromatography at 25°C 
The Sbi-III-IV-NS1 recombinant protein was purified by affinity chromatography using a HisTrapTM 
HP column (GE Healthcare) which was operated using the AKTA purifier system. This system 
measures the conductivity and UV/Vis absorbance at 280 nm indicated as green or blue line, 
respectively. The blue line shows the absorbance at 280 nm. The green line shows the percentage of 
imidazole in the elution buffer (20mM Tris, 300mM NaCl, 500 mM imidazole PH: 7.4). Fractions 




















Figure 8: Expression trials for Sbi-III-IV-NS1 
The figure shows the samples from the first 9 eluted fractions (Lanes 1-9 correspond to fractions A1-
A9) following purification of the supernatant from E. coli expressing the Sbi-III-IV-NS1 fusion 
protein (Figure 6) using AKTA ion affinity chromatography at 25°C run on a 12% SDS gel stained 
with Coomassie blue. The insoluble pellet is shown in the first lane. The presence of the recombinant 
Sbi-III-IV-NS1 protein at 55kDa is shown to be readily present (indicated by arrow) in the insoluble 




Figure 9: Purification of Sbi-III-IV-NS1 on AKTA ion affinity chromatography at 16°C 
The Sbi-III-IV-NS1 recombinant protein was purified by affinity chromatography using a HisTrapTM 
HP column (GE Healthcare) which was operated using the AKTA purifier system. This system 
measures the conductivity and UV/Vis absorbance at 280 nm indicated as green or blue line, 
respectively. The blue line shows the absorbance at 280 nm. The green line shows the percentage of 
imidazole in the elution buffer (20mM Tris, 300mM NaCl, 500mM imidazole, PH: 7.4). Fractions 
were checked for the presence of Sbi-III-IV-NS1 by SDS-PAGE.  
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3.2 Expression of Sbi-III-IV-NS1 into Rosetta ™ 2(DE3) 
Since expression of the recombinant Sbi-III-IV-NS1 protein was not obtained as a 
soluble protein using the E. coli BL21 strain, its derivative E. coli strain RosettaTM 
was used which allows for more stable expression of eukaryotic proteins. The 
Rosetta strain contains plasmids that encode tRNAs for codons rarely used in E. coli 
thus providing a universal translation system. Hence, expression of the Sbi-III-IV-
NS1 construct was attempted in Rosetta with the aim of obtaining recombinant 
protein in a native conformation (soluble) compared to the insoluble inclusion 
bodies obtained when the BL21 strain was used.  
 
Expression in Rosetta cells (100 ml culture) was performed for 18 hours (overnight) 
and 10ml samples were collected at 4, 8 and 12 hours. Two 10ml samples were 
collected at 18 hours. Cells were lysed using sonication - however, one 10ml sample 
collected at 18 hours was treated with both sonication and the BugBuster lysis buffer 
to enhance lysis and release of expressed protein. No discernible difference was 
obtained with Rosetta cells at any timepoint, including the 18-hour sample treated 
with the BugBuster lysis buffer. Similar to expression with BL21 cells, the Sbi-III-
IV-NS1 fusion protein was expressed as insoluble inclusion bodies at 24OC (Figure 
10). 





Figure 10: Expression of Sbi-III-IV-NS1 in Rosetta cells 
This figure shows samples from E. Coli Rosetta cells expressing the Sbi-III-IV-NS1 fusion protein. 
The tracks show samples taken from the overnight induction with IPTG at different time points (4, 8, 
12 and 18 hours) (lanes 2, 3, 4 and 5) which were then lysed by sonication and then run on a 12% 
SDS-PAGE gel and stained with Coomassie blue. The sample shown in Lane 6 was lysed by both the 
BugBuster buffer and by sonication. Lane 7 shows the extract of the sonicated cell pellet at 18 hours 
and lane 1 shows the culture supernatant. The molecular weight ladder is indicated to the far left and 
the arrows show the expected position of the Sbi-III-IV-NS1 fusion protein (55kDa). 
 
3.3 Optimisation of the purification of recombinant Sbi-III-IV-NS1 
from inclusion bodies using Nickel column affinity 
chromatography 
Preliminary experiments had indicated that rather than being expressed as a soluble 
protein the recombinant Sbi-III-IV-NS1 protein was insoluble and accumulated in 
inclusion bodies within the E. coli cells. In order to optimise the purification the 
protein was solublised by using 8M urea and incubated in a series of different 
refolding buffers as mention in the methods section. Following HisGravi Trap 
affinity column purification the recombinant Sbi-III-IV-NS1 protein was eluted with 
PBS buffer containing 300 mM imidazole. The 15 eluted fractions from the different 
refolding buffer incubations were analysed by SDS-PAGE as shown in figure 11. 




Figure 11: Screening of the expressed Sbi-III-IV-NS1 protein in different re-folding buffers 
Following transfection of E. coli with the plasmid containing the Sbi-III-IV-NS1 insert, inclusion 
bodies were purified and exposed to a series of different refolding buffers from the Athena Refolding 
Kit and run on a12% SDS-gel which was stained with Coomassie blue. The gel shows the expected 
band size of Sbi-III-IV-NS1 (55kDa) and buffers 4, 8, 11 and 12 were more likely to be the optimal 
refolding buffers.  
 
On the basis of the results shown in Figure 11 buffers 4, 8 and 12 were chosen to be 
used for refolding and further purification experiments of recombinant Sbi-III-IV-
NS1 using its N-terminal histidine tag by affinity chromatography with a HisGravi 
Trap column (GE Healthcare) as shown in Figures 12, 13 and 14. These are the 
results of 3 separate experiments designed to optimise the imidazole (100-500 mM) 

















Figure 12: Purification of Sbi-III-IV-NS1 following incubation and refolding using buffer 4 
A 12% SDS-gel was stained with Coomassie blue and shows bands of the elution fractions after 
purification with a HisGravi Trap column (GE Healthcare) using different elution concentrations of 
imidazole (300 and 500 mM). The gel shows a major band at the expected molecular weight of 























Figure 13: Purification of Sbi-III-IV-NS1 following incubation and refolding using buffer 8 
A 12% SDS-gel was stained with Coomassie blue and shows bands of the elution fractions after 
purification with the HisGravi Trap column (GE Healthcare) using different elution concentrations of 
imidazole (100-500 mM) to optimise the elution conditions. The gel shows a major band at the 
expected molecular weight of 55kDa following elution with imidazole. F=flow through, W=wash. 
 








100 mM 300 mM
 
Figure 14: Purification of Sbi-III-IV-NS1 following incubation and refolding using buffer 12 
A 12% SDS-gel was stained with Coomassie blue and shows bands of the elution fractions after 
purification with a HisGravi Trap column (GE Healthcare) using different elution concentrations of 
imidazole (100 and 300 mM). The gel shows a major band at the expected molecular weight of 
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3.4 Complement activation assay assessment using the Wieslab kit 
In order to assess complement pathway activity (classical, alternative and MBL) in 
presence of Sbi-III-IV as part of the Sbi-III-IV-NS1 fusion protein, and its ability to 
deplete complement component C3 in Wieslab assay system (72), the soluble fusion 
protein obtained by refolding the protein isolated from inclusion bodies using buffer 
12 of the Athena kit (Figure 14) was added to normal human serum and the mixture 
was then added to mannan, IgM and LPS coated wells to assay the MBL, the 
classical and the alternative pathway, respectively. No complement inhibition was 
detected in any of the three pathways in contrast to human serum (positive control) 
in which complement was shown to be fully active in all pathways (Figure 15 a, b 


































































































Figure 15: Functional activity assessment of the Sbi-III-IV-NS1 fusion protein in complement 
activation 
The soluble and refolded Sbi-III-IV-NS1 fusion protein was mixed with human serum to a final 
concentration of 0.5 mg/ml. The mixture was the diluted to 1% in the classical and the MBL pathway 
diluent and added to IgM or mannan coated wells, respectively (A and C). For the alternative 
pathway assay, serum containing Sbi-III-IV-NS1 fusion protein was diluted to 5.5% in the alternative 
pathway diluent (B). The neo-antigens resulting from complement activation were probed with anti-
C5b-9 antibody. The results show that there is no increase or decrease in the levels of complement 
activation in this assay comparable to normal human serum (positive control) indicating that this 
construct did not cause the depletion of complement component C3 as observed with Sbi-III-IV 
alone.  
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3.5 Circular dichroism (CD) 
Since the Sbi-III-VI-NS1 contains an Sbi-IV domain, which is composed of three 
alpha-helices (73), it was expected that some degree of helicty will be observed in 
the CD data. The unstructured protein 1 (NS1) from Dengue virus is also known to 
contain significant beta-sheet structure (74), which would be expected to give a 
signal observable in the CD spectra in the region of 200-210 nm. The CD spectra 
(Figures 16 & 18), however show no evidence of helical structure in this region 
suggesting that the protein maybe present as a random coiled coil in solution 
because it is unfolded. These results could be simply due to poor signal to noise ratio 
in the region. The poor signal could be due to inaccuracy of measurement (protein 




Figure 16: Smoothed data of 3 scans of the CD spectra of the Sbi-III-IV-NS1 fusion protein in 
PBS 
No peaks were observed in the region scanned, suggesting that the fusion protein was in an unfolded 








Figure 17: CD spectra of Sbi-III-IV-NS1 fusion protein in PBS 
No significant alpha helicity observed in the region scanned, suggesting that the fusion protein was in 
an unfolded state. Series 1-3 represent replicates, series 4 represents an average of the three repeats.  
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Figure 18: Smoothed data of 3 scans of the CD spectra of the Sbi-III-IV-NS1 fusion protein in 
PBS 
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3.6 Western blotting 
Western blotting was performed to confirm the identity of the Sbi-III-IV-NS1 
recombinant protein seen at 55 kDa in the SDS-PAGE experiments. After SDS-
PAGE separated proteins were transferred electrophoretically onto a nitrocellulose 
membrane at 25V for 12 minutes in transfer buffer. Buffer 12 was used for refolding 
in this experiment. Figure 3-14 shows the Sbi-III-IV-NS1 recombinant protein on 
SDS-PAGE with the expected band size of 55 kDa (A) and (B) shows the western 
blot of the gel using polyclonal rabbit anti-Sbi antibody and probed with HRP 
conjugated goat anti-rabbit IgG antibody. The eluted proteins were thus confirmed 












Figure 19: Western blot of Sbi-III-IV-NS1 
A 12% SDS-gel was stained with Coomassie blue and shows bands of the elution fractions of 
refolding buffer 12, after purification with the HisGravi Trap column (GE Healthcare). The gel shows 
eluted fractions and shows a major band at the expected molecular weight of 55 kDa following 
elution with 300mM imidazole (A). Western blot analysis using polyclonal rabbit anti-Sbi antibody 
was used to confirm the identity of the eluted protein (B). 
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Dengue fever is a mosquito-borne tropical disease that affects millions of people, 
which when left untreated, causes mortality in about 50% of cases (1, 2). Dengue 
fever is caused by any of the 5 different serotypes of the dengue virus that have been 
identified. Infection with a specific (DENV) serotype confers lifelong immunity 
against that specific serotype but cross-protection against other serotypes lasts only a 
few months (10). Previous studies have shown that vaccine-mediated localised 
activation of complement factor C3 leads to improved pan-serotype immunological 
memory and opsonisation by phagocytes (59). Thus, the ideal DENV vaccine would 
contain a highly conserved immunogenic DENV protein conjugated to a 
complement activator. Therefore, this study aimed to construct a fusion protein 
comprising the highly-conserved DENV non-structural glycoprotein, NS1, and an 
immune evasion factor of Staphylococcus aureus, Sbi, which interacts with Factor 
H, C3b and C3b and C3d (75).  
In order to achieve this aim the project set out to produce a recombinant protein that 
could both induce an immune response to the conserved DENV non-structural 
protein (NS1) and’ in tandem, induce effective complement activation which would 
lead to highly efficient neutralisation and phagocytosis of infected cells and 
neutralise the infectious pathway. 
Using a previously cloned hybrid Sbi-III-IV-NS1 gene cloned into the expression 
vector pET-28a, methods were optimised with E.coli BL21 and its derivative, 
RosettaTM, to obtain sufficient quantities of the recombinant hybrid protein to initiate 
vaccination strategies. However, although optimization of the expression conditions 
in E. coli allowed abundant quantities of recombinant Sbi-III-IV-NS1 to be 
produced (Figure 6) further experiments demonstrated that the expressed protein 
was not soluble and was found in inclusion bodies within the bacteria. This is not an 
uncommon finding in prokaryotic systems which do not allow appropriate 
glycosylation of eukaryotic derived proteins. In addition, the induction of the 
expression of the fusion protein with the prokaryotic promoter T7 and/or the absence 
of the appropriate eukaryotic cellular machinery in E. coli BL21 (and its derivative, 
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RosettaTM) required to maintain the fusion protein in its native state, may have led to 
the expression of the denatured fusion protein in inclusion bodies (76).  
In order to try and isolate the expressed recombinant Sbi-III-IV-NS1 from the 
inclusion bodies, E. coli cells were first sonicated and the Sbi-III-IV-NS1 
recombinant protein was first purified by affinity chromatography (Figures 7 and 9). 
However, no peaks of eluted proteins were observed and elution fractions run on 
SDS-PAGE showed no bands (Figure 8). This implied that no soluble proteins were 
present in the extract and the recombinant protein was effectively trapped in 
inclusion bodies, which has been described elsewhere (76). 
 
Therefore, further experiments were performed in order to firstly release the 
denatured Sbi-III-IV-NS1 recombinant protein and, secondly, to solubilise it and 
allow the protein to refold into is native conformation. 
 
Clearly stringent conditions were required to release and solubilise the denatured 
protein so the E. coli BL2 cultured bacteria were lysed and sonicated and the extract 
solubilised in 8M urea following which the protein concentration was adjusted to 
1mg/ml and using the ‘drip technique’ was allowed to refold in a series of buffers 
designed to promote protein refolding as mention in the methods section. Following 
overnight incubation in the refolding buffer the Sbi-III-IV-NS1 recombinant protein 
was isolated using HisGravi Trap affinity column purification and conditions for 
optimal elution with imidazole was performed (Figures 12, 13 and 14). 
 
Attempts to refold the protein from the inclusion bodies were not very successful 
with the best results being obtained when polyethylene glycol (PEG) [i.e. in buffer 
4] was excluded from the isolation buffers, which could have enhanced the activity 
of Triton X-100, a non-ionic detergent that improves the solubility of proteins 
(Figures 12). However, circular dichroism experiments on the purified and refolded 
recombinant Sbi-III-IV-NS1 protein (Figure 16-18) were inconclusive. Circular 
dichroism is a method which allows the determination of the secondary refolded 
structure of the refolded recombinant Sbi-III-IV-NS1 protein but the Chirascan 
failed to register any protein helical structural motifs as would be expected from the 
published molecular models of Sbi-IV. In addition the non-structural protein 1 
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(NS1) from Dengue virus is known to contain significant beta-sheet structure (74) 
but again no signal was observed in the circular dichroism scan. This evidence 
therefore suggests that the numerous attempts to purify and appropriately refold the 
Sbi-III-IV-NS1 protein were ultimately unsuccessful.  
While the clear advantage of using a mammalian expression system would be that 
proteins would be glycosylated and therefore remain stable and be more likely to 
remain in solution, it was thought that it might be preferable to use an E. coli 
expression system because of the need to produce sufficiently large amounts of the 
fusion protein that would allow testing in the in vitro assays that were established. 
Converse to mammalian expression systems involving cell lines such as the human 
embryonic kidney (HEK-293) and Chinese hamster ovary (CHO) cell lines, E. coli 
systems offer rapid and high expression of recombinant proteins. Furthermore, use 
of a mammalian expression system would have involved the generation of stable cell 
lines that would express the fusion proteins; a time-consuming process that could be 
complicated further by clonal variations and the need to keep the transgene stable 
under selection pressure.  
Since the expression of soluble recombinant protein in E. coli can be influenced by 
different factors, such as temperature and IPTG concentration, in future studies, the 
expression of Sbi-III-IV-NS1 fusion protein will be assessed at different 
temperatures and lower (<1mM) IPTG concentrations in RosettaTM cells. It is 
expected optimization of temperature and IPTG concentrations will increase yields 
of the native Sbi-III-IV-NS1 fusion protein. Expression of the individual 
components of the Sbi-III-IV-NS1 fusion protein separately, i.e. Sbi-III-IV by its 
own and NS1 alone, may be productive as a reduction in the complexity of the 
fusion protein may be responsible for its inability to fold correctly. Pooling of the 
individual proteins (Sbi-III-IV and NS1) in subsequent assays would then be 
attempted. 
As NS1 is commonly secreted as an hexameric complex into the plasma of Dengue 
fever patients (63, 77) oxidation-dependent disulphide bond formation between the 
cysteine residues of the Sbi-III-IV-NS1 fusion protein (which possesses six potential 
disulphide bonds), is likely to be somewhat ineffective in the reductive cytoplasmic 
environment of E. coli (78). To counter the effect of reductases such as trxB (a 
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thioredoxin reductase) present in the cytoplasm, an E. coli strain containing the trxB 
mutation could be utilised. As the reductive activities of Thioredoxin-1 and -2 
(encoded by trxA and trxC respectively) is dependent on their initial reduction by the 
gene product of trxB, only non-reduced forms of the thioredoxins will be present in 
the cytoplasm in a trxB mutant. These non-reduced thioredoxins can catalyse 
disulphide bond formation (79) thereby possibly promoting the stability of the 
recombinant Sbi-III-IV-NS1 fusion protein and its expression within the cytoplasm 
in a soluble form. This method has been successfully used to express sufficient 
amounts of cysteine-rich extracellular proteins such as the micronemal adhesive 
protein from Toxoplasma gondii (80). Obtaining functional isoforms of the fusion 
protein will therefore be tried using the E. coli trxB mutant expression system 
(commercially available as Origami™ 2(DE3)pLysS) or by targeting the expressed 
protein to the E. coli periplasm where disulphide bond-promoting enzymes abound 
to optimise appropriate folding of the protein. 
In addition to using a strain with reduced reductase activity, co-expression of the 
Sbi-III-IV-NS1 protein with plasmids containing coding sequences for disulphide 
oxidoreductase and isomerase, DsbA and DsbC respectively, may ensure stability of 
the Sbi-III-IV-NS1 fusion protein as both DsbA and DsbC play crucial roles in the 
stability and functional expression of proteins in vivo(81, 82). Alternatively, the Sbi-
III-IV-NS1 construct could be engineered to include a signal sequence that will 
target the expressed protein to the periplasm where the Dsb family of proteins is 
present.  
 
In the Athena refolding kit experiments perhaps the optimal refolding was achieved 
with buffer 4 as judged by SDS-PAGE (Figure 12) and this could be confirmed with 
appropriate CD analysis. In future experiments detailed CD analysis of the Sbi-III-
IV-NS1 protein should be undertaken to see whether the protein is expressed in its 
native confirmation. Further experiments might yield more definitive data if a higher 
concentration of protein and/or an increased number of scans were used to improve 
the signal to noise ratio. 
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Alternatively, the production of the fusion protein could be performed in the 
aforementioned mammalian expression systems (HEK-293 or CHO cell lines) or in 
baculovirus-infected insect cell lines (83). Despite the limitations mentioned 
previously, the key advantage of utilizing either insect or mammalian cell lines over 
the E. coli system would be the production of soluble recombinant proteins more 
likely to be expressed in their native conformation. These insect or mammalian 
systems provide glycosylation and other post-translational modifications, which 
could improve the solubility of the Sbi-III-IV-NS1 fusion protein. Exploiting the 
baculovirus vector system in lepidopteron cells and larvae (84) could be more 
productive since this system, termed MultiBac, affords the possibility of co-
expressing the Sbi-III-IV and NS1 subunits in separate bacmids to yield the 
functional Sbi-III-IV-NS1 fusion protein complex. Following soluble protein 
expression, purification of the Sbi-III-IV-NS1 fusion protein secreted into growth 
media could be achieved using conventional monoclonal antibody-dependent 
immune-purification techniques (62) identified several monoclonal antibodies that 
bound to 3 highly-conserved epitopes of the NS1 protein. These antibodies, when 
covalently-bound to Protein G-matrices via crosslinking agents, could be used to 
isolate the soluble Sbi-III-IV-NS1 fusion protein from growth media.  
 
Successful expression of the soluble Sbi-III-IV-NS1 fusion protein and its individual 
components (whose expression will be pursued as described previously) will pave 
the way for experiments in which the functional immunogenicity of the different 
proteins, i.e. their ability to induce neutralising antibodies, will be compared in mice 
(i.e. Sbi-III-IV-NS1 versus Sbi-III-IV and Sbi-III-IV-NS1 versus NS1). 
 
In summary, an ideal vaccine for DENV will include antigenic components that are 
highly conserved among all described serotypes of DENV and can induce long-term 
immunological memory. The fusion protein described in this study satisfies vaccine 
candidacy as it contains the highly-conserved DENV non-structural protein NS1 and 
the Staphylococcal complement activator, Sbi. This fusion protein was successfully 
expressed in this study but not in a soluble, biologically-active state. To obtain 
functional isoforms of the fusion protein stability of the protein in the E. coli 
expression system should be pursued by utilising an E. coli trxB mutant 
(commercially available as Origami™ 2(DE3)pLysS) or by targeting the expressed 
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protein to the E. coli periplasm where disulphide bond-promoting enzymes can 
promote appropriate folding of the protein. 
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5 Summary, conclusions and future work 
 
The purpose of the project was to develop a method for enhancing the development 
of effective immunity against Dengue Fever. It has previously been shown that the 
recruitment of C3d greatly enhances humoral immunity so therefore the aim of the 
project was to directly associate Sbi from staphylococcus (which activates the 
alternative complement pathway and indirectly recruits C3d) to NS1 a key target for 
immunoprotection against DENV. The aim of the project has therefore to express 
and produce sufficient quantities of Sbi-III-IV-NS1 for vaccine studies. However, 
firstly a number of hurdles had to be overcome, notably determining the optimal 
conditions for Sbi-III-IV-NS1 expression using different E. coli strains and different 
culture conditions including, time, temperature and IPTG concentration. Secondly it 
became clear that the Sbi-III-IV-NS1 protein was not present in soluble extracts of 
the transformed E. coli BL2 bacteria and that the Sbi-III-IV-NS1 recombinant 
protein was expressed in a denatured form in inclusion bodies. A number of methods 
were then used to optimize the isolation and the appropriate refolding of the Sbi-III-
IV-NS1 recombinant protein which were assessed by SDS-PAGE and CD. Although 
significant progress was made there was insufficient time to progress to the next 
stage of the project which was to use the purified Sbi-III-IV-NS1 protein to assess 
its ability to produce resistance to DENV (in mice) using the construct to recruit C3d 
which should enhance humoral immunity to the virus and pave the way for future 
















Firstly, future studies could assess the expression of the Sbi-III-IV-NS1 fusion 
protein at different temperatures and lower (<1mM) IPTG concentrations in 
RosettaTM cells as well as trying to express the individual components Sbi-III-IV 
and NS1 separately as the complexity of the fusion protein may contribute to its lack 
of solubility and inability to fold appropriately. 
Secondly, as refolding of this recombinant protein is dependent of the formation of a 
number of disulphide bonds the effect of reductases such as trxB (a thioredoxin 
reductase) present in the cytoplasm, an E. coli strain containing the trxB mutation 
could be utilized. In addition, plasmids containing coding sequences for disulphide 
oxidoreductase and isomerase may improve the stability of the Sbi-III-IV-NS1 
fusion protein or, alternatively, the Sbi-III-IV-NS1 construct could be engineered to 
include a signal sequence that will target the expressed protein to the periplasm 
where the Dsb family of proteins is present.  
Finally, if ssuccessful expression of a soluble form of the Sbi-III-IV-NS1 fusion 
protein and its individual components can be achieved it will then be possible to 
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7.1 Appendix 1 
7.1.1 Sbi-III-IV-NS1 conjugate. 
 
The coding sequence of Sbi domains 3 and 4 was cloned into the pET28a 
(Kanr)vector using the NheI and BamHI restriction sites and, in addition, the coding 
sequence of Dengue virus NS1 was inserted using the BamHI and XhoI restriction 
sites to make a plasmid construct that could be expressed in E. coli. The 
recombinant Sbi-III-IV-NS1 carried an N-terminal His-tag for protein purification. 
(This work was performed by Dr Gyles Cozier). Sbi-III-IV is in red. NS1 is in blue. 
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(HisTag)                    (Thrombin) 
ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG CGC GGC AGC CAT 
 M   G   S   S   H   H   H   H   H   H   S   S   G   L   V   P   R   G   S   H 
   (NheI) 
ATG GCT AGC GAA CGT CAA AAT ATT GAA AAT GCG GAT AAA GCA ATT AAA GAT TTC CAA GAT 
 M   A   S   E   R   Q   N   I   E   N   A   D   K   A   I   K   D   F   Q   D 
 
AAC AAA GCA CCA CAC GAT AAA TCA GCA GCA TAT GAA GCT AAC TCA AAA TTA CCT AAA GAT 
 N   K   A   P   H   D   K   S   A   A   Y   E   A   N   S   K   L   P   K   D 
 
TTA CGC GAT AAA AAT AAC CGC TTT GTA GAA AAA GTT TCA ATT GAA AAA GCA ATC GTT CGT 
 L   R   D   K   N   N   R   F   V   E   K   V   S   I   E   K   A   I   V   R 
 
CAT GAT GAG CGT GTG AAA TCA GCA AAT GAT GCA ATC TCA AAA TTA AAT GAA AAA GAT TCA 
 H   D   E   R   V   K   S   A   N   D   A   I   S   K   L   N   E   K   D   S 
 
ATT GAA AAC AGA CGT TTA GCA CAA CGT GAA GTT AAC AAA GCA CCT ATG GAT GTA AAA GAG 
 I   E   N   R   R   L   A   Q   R   E   V   N   K   A   P   M   D   V   K   E 
 
CAT TTA CAG AAA CAA TTA GAC GCA TTA GTA GCT CAA AAA GAT GCT GAA AAG AAA GTG GCG 
 H   L   Q   K   Q   L   D   A   L   V   A   Q   K   D   A   E   K   K   V   A 
(BamHI) 
GGA TCC GAC AGT GGT TGC GTT GTG AGC TGG AAG AAC AAA GAA CTG AAA TGC GGC AAT GGG 
 G   S   D   S   G   C   V   V   S   W   K   N   K   E   L   K   C   G   N   G 
 
ATA TTT GTC ACA GAT AAC GTG CAT ACA TGG ACA GAA CAA TAC AAG TTC CAA CCA GAA TCC 
 I   F   V   T   D   N   V   H   T   W   T   E   Q   Y   K   F   Q   P   E   S 
 
CCT TCA AAA CTG GCT TCA GCT ATT CAG AAA GCT CAT GAA GAG GGC ATT TGT GGA ATC CGC 
 P   S   K   L   A   S   A   I   Q   K   A   H   E   E   G   I   C   G   I   R 
 
TCA GTA ACA AGA CTG GAA AAT CTT ATG TGG AAA CAG ATA ACA CCG GAA TTG AAC CAC ATC 
 S   V   T   R   L   E   N   L   M   W   K   Q   I   T   P   E   L   N   H   I 
 
CTA TCA GAA AAT GAA GTG AAG CTG ACT ATC ATG ACA GGA GAC ATT AAA GGA ATC ATG CAG 
 L   S   E   N   E   V   K   L   T   I   M   T   G   D   I   K   G   I   M   Q 
 
GTA GGA AAA CGA TCT CTG CAG CCC CAA CCC ACT GAG CTG AGG TAT TCA TGG AAA ACA TGG 
 V   G   K   R   S   L   Q   P   Q   P   T   E   L   R   Y   S   W   K   T   W 
 
GGT AAA GCA AAA ATG CTC TCC ACA GAA CTC CAC AAC CAG ACC TTC CTT ATT GAT GGT CCC 
 G   K   A   K   M   L   S   T   E   L   H   N   Q   T   F   L   I   D   G   P 
 
GAA ACA GCA GAA TGC CCC AAC ACA AAC AGA GCT TGG AAT TCA CTG GAA GTT GAG GAC TAT 
 E   T   A   E   C   P   N   T   N   R   A   W   N   S   L   E   V   E   D   Y 
 
GGC TTT GGA GTA TTC ACC ACC AAT ATA TGG CTA AAA TTG AGA GAG AAG CAG GAT GTA TTT 
 G   F   G   V   F   T   T   N   I   W   L   K   L   R   E   K   Q   D   V   F 
 
TGT GAC TCA AAA CTT ATG TCA GCG GCC ATA AAG GAC AAC AGA GCC GTC CAT GCT GAT ATG 
 C   D   S   K   L   M   S   A   A   I   K   D   N   R   A   V   H   A   D   M 
 
GGT TAT TGG ATA GAA AGT GCA CTC AAT GAC ACA TGG AAG ATA GAA AAA GCC TCT TTC ATT 
 G   Y   W   I   E   S   A   L   N   D   T   W   K   I   E   K   A   S   F   I 
 
GAA GTT AAA AGT TGC CAC TGG CCA AAG TCA CAC ACT CTT TGG AGC AAT GGA GTG CTA GAA 
 E   V   K   S   C   H   W   P   K   S   H   T   L   W   S   N   G   V   L   E 
 
AGT GAG ATG ATA ATT CCA AAG AAT CTC GCT GGA CCA GTG TCA CAA CAC AAT AAC AGA CCA 
 S   E   M   I   I   P   K   N   L   A   G   P   V   S   Q   H   N   N   R   P 
 
GGC TAT TAC ACA CAA ACA GCA GGA CCT TGG CAT CTA GGC AAA CTT GAG ATG GAC TTT GAT 
 G   Y   Y   T   Q   T   A   G   P   W   H   L   G   K   L   E   M   D   F   D 
 
TTC TGC AAA GGA ACT ACA GTG GTG GTG ACC GAG GAC TGT GGA AAC AGA GGA CCC TCT TTA 
 F   C   K   G   T   T   V   V   V   T   E   D   C   G   N   R   G   P   S   L 
 
AGA ACA ACC ACT GCC TCT GGA AAA CTT ATA ACG GAA TGG TGC TGT CGA TCT TGC ACA TTG 
 R   T   T   T   A   S   G   K   L   I   T   E   W   C   C   R   S   C   T   L 
 
CCA CCG TTA AGA TAC AGA GGT GAG GAT GGA TGC TGG TAT GGG ATG GAA ATT AGA CCA TTG 
 P   P   L   R   Y   R   G   E   D   G   C   W   Y   G   M   E   I   R   P   L 
 
AAA GAG AAA GAA GAA AAT CTG GTC AAC TCC TTG GTC ACA GCC STOP 
 K   E   K   E   E   N   L   V   N   S   L   V   T   A 
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 The purification of expressed Sbi-III-IV-NS1 by AKTA affinity chromatography 
using different conditions.  
 
 ALISBI34NS123032015:10_UV1_280nm  ALISBI34NS123032015:10_Conc  ALISBI34NS123032015:10_Fractions
 ALISBI34NS123032015:10_Inject  ALISBI34NS123032015:10_Logbook
-1000
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Purification of Sbi-III-IV-NS1 by AKTA affinity chromatography at 16oC 
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7.3 Appendix 3 
7.3.1 Buffers and solutions 
7.3.1.1 Protocol to process Inclusion body pellets  
 
Solubilisation buffer (25 mM Tris-HCL pH 7.5, 8 M Urea with 5 mM DDT at 
pH 8) 50 ml 
 
 
1 Lysis buffer (lysosome)  
 
(25mM Tris-HCL pH 8.0, 150 mM NaCl, 0.5 
mg/ml lysozyme, 1 mM EDTA) 50 ML 
2 Wash buffer (Triton) 
 
(25 mM Tris-HCL pH 8.0, 0.5 M NaCL, 0.5% 
Triton X-100, 1 mM EDTA) 50 ML 
3 Wash buffer (Urea) 
 
(25mM Tris-HCL pH 8.0, 0.5 M NaCl, 1 
mg/ml Sodium deoxycholic, 1 M Urea) 50 ML 
 
 
7.3.1.2 Refolding Buffers from the Athena kit 
 
Buffer 4 50 mM MES pH 6.0, 240 mM NaCl, 10 mM KCl, 2 mM MgCl2, 2 
mM CaCl2, 0.5 M arginine, 0.5% Triton X-100, 1 mM GSH, 0.1 
mM GSSH 
Buffer 6 50 mM MES pH 6.0, 240 mM NaCl, 10 mM KCl, 1 mM EDTA, 
0.5 M arginine, 0.4 M sucrose, 0.5% Triton X-100, 0.05% 
polyethylene glycol 3550, 1 mM GSH, 0.1 mM GSSH 
 
Buffer 8 50 mM Tris-Cl pH 8.5, 9.6 mM NaCl, 0.4 mM KCl, 2 mM MgCl2, 
2 mM CaCl2, 0.4 M sucrose, 0.5% Triton X-100, 0.05% 
polyethylene glycol 3550, 1 mM GSH, 0.1 mM GSSH 
 
Buffer 12 50 mM Tris-Cl pH 8.5, 240 mM NaCl, 10 mM KCl, 1 mM EDTA, 
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7.3.1.5.1 Separating gel 12% 
Tris (ph8) 1.5625 ml 
Acrylamide 1.867 ml 
Water 2.77 ml 
TEMED 2.8125 ul 
APS 10% 31.25   ul 
 
7.3.1.5.2 Staking gel  
0.5 M Tris (pH6.8) 0.7813 ml 
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Acrylamide 0.3125 ml 
Water 2 ml  
TEMED 3.125 ul 










7.4 Appendix 4 
7.4.1 Media 
7.4.1.1 Luria broth 
10 gm Bacto Tryptone 
5 gm Yeast extract 
10 gm NaCl 
Total volume  1000 ml 
 
7.4.1.2 Stock Solution Preparation of 1 M IPTG 
2.38 gm IPTG 
5 gm Yeast extract 
Filter 0.22 μ syringe filter 
Total final volume 10 ml 
 
